RA Capital Management and Oncology

Selected healthcare news for the capital firm - RA Capital Management, and the healthcare topic - Oncology. We have 42 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/20/2021 RA Capital Management L.P. Purchases Shares of 350,000 Cullinan Oncology, Inc. (NASDAQ:CGEM) RA Capital Management L.P. purchased a new stake in Cullinan Oncology, Inc. (NASDAQ:CGEM) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 350,000 shares of the company‚Aos stock, valued at approximately $14,585,000. Several other hedge funds and other institutional investors have also made changes to their positions in the business. MPM Oncology Impact Management LP ...
4/29/2021 Boundless Bio corrals $105M financing round to prep aggressive cancer programs for clinic | FierceBiotech FierceBiotech Boundless Bio has wrapped a $105 million series B financing to launch the company's extrachromosomal DNA (ecDNA) programs for aggressive cancers into the clinic.The financing was co-led by RA Capital Management and Nextech Invest and also included Fidelity Management & Research Company LLC, Redmile Group, Wellington Management and others.Launched in 2019, Boundless is developing precision oncology drugs targeting ecDNA cancers that have resisted treatment. Since raising $46 million ...
4/29/2021 Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) ... RA Capital Management, with participation from new investors Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, and Logos Capital and existing investorsFunding will support development of ecDNA directed therapeutic programs and ecDNA companion diagnostic to address oncogene amplified cancersApril 28, 2021 07:30 AM Eastern Daylight TimeSAN DIEGO--( BUSINESS WIRE )-- Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed ...
4/28/2021 The Briefing: Zomato Files For IPO, Boundless Bio Raises $105M, And More – Crunchbase News ... oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, raised $105 million in a Series B financing led by RA Capital Management and Nextech Invest .Caresyntax raises $100M: Boston-based Caresyntax , developer of a digital surgery platform, raised $100 million in a Series C funding round led by PFM Health Sciences . The company uses AI-enabled software to analyze large volumes of real-world data in and ...
4/28/2021 The Briefing: Zomato Files For IPO, Boundless Bio Raises $105M, And More ... oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, raised $105 million in a Series B financing led by RA Capital Management and Nextech Invest .Caresyntax raises $100M: Boston-based Caresyntax , developer of a digital surgery platform, raised $100 million in a Series C funding round led by PFM Health Sciences . The company uses AI-enabled software to analyze large volumes of real-world data in and ...
4/28/2021 Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) | Business Wire Business Wire ... oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ec DNA H arboring O ncogenes (ECHO‚N¢) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.RA Capital Management and ...
4/28/2021 ... oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ec DNA H arboring O ncogenes (ECHO‚N¢) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.RA Capital Management and ...
4/28/2021 Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) Venture Capital Database 2021 Now Available! Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) Led by Nextech Invest and RA Capital Management, with participation from new investors Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, and Logos Capital and existing investors Funding will support development of ecDNA directed therapeutic programs and ...
4/28/2021 Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) | Financial Buzz ... oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ec DNA H arboring O ncogenes (ECHO‚N¢) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.RA Capital Management and ...
4/9/2021 Werewolf Therapeutics files for IPO - MarketWatch MarketWatch Werewolf Therapeutics Inc., which is developing cancer drugs using its Predator protein engineering technology, filed for an initial public offering.The Cambridge, Mass., company has applied for a Nasdaq Global Market listing under symbol HOWL.Werewolf said in January that it completed its $72 million Series B financing, led by RA Capital Management. According to the filing, RA Capital has a 11.25% stake. MPM Capital owns 20.75%, and an oncology ...
4/8/2021 Werewolf Therapeutics files for IPO - MarketWatch MarketWatch Werewolf Therapeutics Inc., which is developing cancer drugs using its Predator protein engineering technology, filed for an initial public offering.The Cambridge, Mass., company has applied for a Nasdaq Global Market listing under symbol HOWL.Werewolf said in January that it completed its $72 million Series B financing, led by RA Capital Management. According to the filing, RA Capital has a 11.25% stake. MPM Capital owns 20.75%, and an oncology ...
4/7/2021 Biologics vs. cancer | Drug Discovery News CAMBRIDGE, Mass.‚AiPyxis Oncology recently announced the closing of a $152-million Series B financing, led by Arix Bioscience and co-led by RTW Investments, LP, with participation from additional new investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company ...
3/30/2021 Pyxis Oncology closes $152M Series B Pyxis Oncology closes $152M Series B March 30, 2021 By Sean WhooleyBiologics developer Pyxis Oncology announced today that it closed a Series B financing round worth $152 million.Cambridge, Mass.-based Pyxis had its ... according to a news release.New investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management, Acuta Capital Partners ...
3/30/2021 Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics Venture Capital Database 2021 Now Available! Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics -- New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I ... LP, with participation from additional new investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta ...
3/29/2021 After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B FierceBiotech It‚Aos been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded ... co-led by RTW Investments, with help from Perceptive Advisors, RA Capital Management, Pfizer Ventures, and a host of others. This also brings its total funding to date up to $174 million, showing just how ...
3/23/2021 Who are the Institutional Holders in iTeos Therapeutics Inc. (ITOS)? ... shares outstanding are 35.05M, and float is at 34.80M with Short Float at 1.34%. Institutions hold 71.59% of the Float. RA Capital Management, L.P. with over 4.42 million shares valued at $149.39 million. The investor ... representing 10.58% and valued at over $125.36 million, while MPM ONCOLOGY IMPACT MANAGEMENT LP holds 6.72% of the shares totaling 2.36 million with a market value of $79.66 million.iTeos Therapeutics Inc. (NASDAQ: ITOS) is ...
3/23/2021 Here is a breakdown of major shareholders in Cardiff Oncology Inc. (NASDAQ: CRDF) Here is a breakdown of major shareholders in Cardiff Oncology Inc. (NASDAQ: CRDF) By - March 22, 202180 institutions hold shares in Cardiff Oncology Inc. (CRDF), with 90.41k shares held by insiders accounting for 0.24% while institutional investors hold 63.12% of the company‚Aos shares. The shares outstanding are 35.67M, and float is at 35.24M with Short Float at 15.20%. Institutions hold 62.97% of the Float. RA Capital Management, L.P ...
3/3/2021 Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology ... RA Capital Management, as well as existing investors, Bregua and Correlation Ventures. In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management, will join the Board of Directors. Janux¬is proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies. The financing will be used to advance Janux¬is ...
3/3/2021 Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology | Financial Buzz ... RA Capital Management, as well as existing investors, Bregua and Correlation Ventures. In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management, will join the Board of Directors. Janux‚Aos proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies. The financing will be used to advance Janux‚Aos ...
3/3/2021 Janux Therapeutics raises $56M Series A for T cell engager tech ... RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner Jake Simson will join Janux‚Aos board of directors, according to a news release.Funding is set to help San Diego-based Janux as it develops its proprietary tumor-activated T cell engager (TRACTr) technology designed to overcome the current limitations in T cell immuno-oncology therapies ...
2/26/2021 The Ridgway Record Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a ... an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX ...
2/26/2021 Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies ... Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies SAN DIEGO, February 26, 2021-- Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells ... an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX ...
2/26/2021 Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies | Financial Buzz Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a ... an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX ...
2/24/2021 Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs | Financial Buzz ... Group. Additional new investors in the raise include SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital ... platform technologies, we are building a robust pipeline of precision oncology and immunology programs,‚Au said Jeffrey Hatfield, chief executive officer of Vividion. ‚AuWe‚Aore excited to have attracted such a distinguished group of healthcare ...
2/24/2021 Xilio raises $95M to take twists on Yervoy and IL-2 into clinic | FierceBiotech FierceBiotech ... to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.Immuno-oncology drugs are typically given systemically, causing them to trigger immune responses that affect healthy ... new backers including Bain Capital Life Sciences, Deerfield Management and RA Capital Management. Existing Xilio investors including Atlas Venture, SV Health Investors and Takeda Ventures also contributed to the financing.Xilio will use the money ...